Stock Track | Viatris Stock Soars as Q3 Results Beat Estimates on Robust New Drug Demand

Stock Track11-08

Shares of Viatris Inc. (VTRS) surged a staggering 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by strong demand for its newly launched generic drugs.

For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, beating the consensus forecast of $3.71 billion.

The company's impressive performance was driven by robust sales of its recently introduced generic versions of popular drugs like AstraZeneca's asthma inhaler Symbicort and Takeda's ADHD medication Vyvanse. Revenue from new product launches totaled $133 million in the third quarter, contributing significantly to the overall revenue beat.

"We continue to make excellent progress executing on our debt paydown commitment and are on pace to achieve our long-term gross leverage target of ~3.0x by year-end," said Viatris CFO Doretta Mistras.

While reaffirming its full-year revenue guidance in the range of $14.6 billion to $15.1 billion, Viatris slightly lowered its adjusted earnings per share forecast to $2.56 to $2.71, from the previous estimate of $2.58 to $2.73. The company cited higher expected R&D costs related to its licensing agreement for Lexicon's diabetes drug sotagliflozin as the reason for the EPS guidance revision.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184610928?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 05:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184610928","market":"hk","top_or_hot":-1,"title":"Stock Track | Viatris Stock Soars as Q3 Results Beat Estimates on Robust New Drug Demand","media":"Stock Track","content":"<p>Shares of Viatris Inc. (VTRS) surged a staggering 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by strong demand for its newly launched generic drugs.</p>\n\n<p>For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, beating the consensus forecast of $3.71 billion.</p>\n\n<p>The company's impressive performance was driven by robust sales of its recently introduced generic versions of popular drugs like AstraZeneca's asthma inhaler Symbicort and Takeda's ADHD medication Vyvanse. Revenue from new product launches totaled $133 million in the third quarter, contributing significantly to the overall revenue beat.</p>\n\n<p>\"We continue to make excellent progress executing on our debt paydown commitment and are on pace to achieve our long-term gross leverage target of ~3.0x by year-end,\" said Viatris CFO Doretta Mistras.</p>\n\n<p>While reaffirming its full-year revenue guidance in the range of $14.6 billion to $15.1 billion, Viatris slightly lowered its adjusted earnings per share forecast to $2.56 to $2.71, from the previous estimate of $2.58 to $2.73. The company cited higher expected R&D costs related to its licensing agreement for Lexicon's diabetes drug sotagliflozin as the reason for the EPS guidance revision.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Viatris Stock Soars as Q3 Results Beat Estimates on Robust New Drug Demand</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Viatris Stock Soars as Q3 Results Beat Estimates on Robust New Drug Demand\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-08 05:40 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Viatris Inc. (VTRS) surged a staggering 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by strong demand for its newly ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VTRS","symbol_name":"Viatris Inc.","start_time":0,"source_url":"","article_id":"1184610928","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184610928","pubTimestamp":1731015651,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Viatris Inc.  surged a staggering 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by strong demand for its newly launched generic drugs.For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, beating the consensus forecast of $3.71 billion.\"We continue to make excellent progress executing o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VTRS":"Viatris Inc."},"translate_title":"由于新药需求强劲，第三季度业绩超出预期，Viatris股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTRS":1},"content_text":"Shares of Viatris Inc. (VTRS) surged a staggering 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by strong demand for its newly launched generic drugs.\nFor the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, beating the consensus forecast of $3.71 billion.\nThe company's impressive performance was driven by robust sales of its recently introduced generic versions of popular drugs like AstraZeneca's asthma inhaler Symbicort and Takeda's ADHD medication Vyvanse. Revenue from new product launches totaled $133 million in the third quarter, contributing significantly to the overall revenue beat.\n\"We continue to make excellent progress executing on our debt paydown commitment and are on pace to achieve our long-term gross leverage target of ~3.0x by year-end,\" said Viatris CFO Doretta Mistras.\nWhile reaffirming its full-year revenue guidance in the range of $14.6 billion to $15.1 billion, Viatris slightly lowered its adjusted earnings per share forecast to $2.56 to $2.71, from the previous estimate of $2.58 to $2.73. The company cited higher expected R&D costs related to its licensing agreement for Lexicon's diabetes drug sotagliflozin as the reason for the EPS guidance revision.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184610928"}